BioCryst Pharmaceuticals, Inc.

NASDAQ:BCRX

Biotechnology

Healthcare
$7.32 +1.02%

+$0.09 today

Market cap
$1.88B
Beta
0.56
P/E (TTM)
-4.8
EPS (TTM)
-$1.89
52W Low $6.00High $10.32

Volume 3.78M

Average 4.85M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

$329.88M

FY 2025 · Annual

Investing Cash Flow

-$13.69M

FY 2025 · Annual

Financing Cash Flow

-$332.44M

FY 2025 · Annual

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(184.06M)(247.12M)(226.54M)(88.88M)263.86M
Depreciation & Amortization777K1.44M1.66M1.25M1.39M
Deferred Income Tax00000
Stock-Based Compensation34.64M44.7M55.62M65.41M85.07M
Change in Working Capital8.12M(58.95M)(32.4M)(87.28M)(56.9M)
Accounts Receivables(20.82M)(21.47M)(6.1M)(22.7M)(36.81M)
Inventory(8.77M)(12.42M)(1.45M)(4.16M)(1.64M)
Accounts Payables39.41M(22.36M)(16.81M)(62.38M)57.8M
Other Working Capital(1.7M)(2.69M)(8.05M)1.96M(76.26M)
Other Non-Cash Items(1.64M)98.07M106.53M57.48M36.46M
Operating Cash Flow(142.16M)(161.85M)(95.14M)(52.02M)329.88M
Capital Expenditures(2.39M)(1.35M)(2.17M)(1.12M)(2.47M)
Acquisitions (Net)0000(6.18M)
Purchases of Investments(10.01M)(244.28M)(514.41M)(266.76M)(262.24M)
Sales of Investments28.2M117.4M385.08M320.48M256.65M
Other Investing Activities0000550K
Investing Cash Flow15.8M(128.24M)(131.5M)52.59M(13.69M)
Debt Repayment293.87M73.07M58.38M(1.7M)(332.77M)
Common Stock Issued50.06M190K342K34K9.17M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities15.73M14.77M(26.24M)(4.09M)(8.85M)
Financing Cash Flow359.67M88.03M32.49M(5.76M)(332.44M)
Effect of Forex Changes71K566K362K(936K)(87.07M)
Net Change in Cash233.39M(201.5M)(193.79M)(6.12M)(103.32M)
Free Cash Flow(144.54M)(163.2M)(97.31M)(53.14M)327.41M

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income$263.9M
+ D&A$1.4M
+ Stock-Based Comp$85.1M
+ Deferred Tax$0
- Working Capital-$56.9M
+ Other Non-Cash$36.5M
= Operating Cash Flow$329.9M
- Capex-$2.5M
= Free Cash Flow$327.4M

Analysis

FY2025 free cash flow is $327.4M. FCF conversion is 124.1% of net income. Operating cash flow was $329.9M, with capex of -$2.5M. The largest bridge item is Stock-Based Comp at $85.1M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13GSC 13G filingNov 10, 2026
8-KCurrent reportNov 4, 2026
10-QQuarterly reportNov 4, 2026
4Statement of changes in beneficial ownershipSep 2, 2026
4Statement of changes in beneficial ownershipSep 2, 2026

Does BCRX generate free cash flow?

BioCryst Pharmaceuticals, Inc. (BCRX) generated $327.41M of free cash flow in fiscal 2025.

How much operating cash flow does BCRX produce?

Operating cash flow was $329.88M, before capital expenditures of $2.47M.